NR 565 Pharmacotherapeutics for Primary
Care Week 1 Quiz 20-Question Practice Quiz
ACTUAL EXAM 2026/2027 | Chamberlain
NR 565 Week 1 | Verified Q&A | Pass
Guaranteed - A+ Graded
Section 1: Pharmacokinetics (Questions 1–4)
Q1: A 68-year-old patient with chronic heart failure and NASH-related cirrhosis is prescribed a new
medication that undergoes extensive first-pass metabolism in the liver. Which pharmacokinetic
alteration is most expected in this patient?
A. Decreased drug bioavailability
B. Increased drug half-life
C. Decreased volume of distribution
D. Increased protein binding
Correct Answer: B
Rationale: Hepatic cirrhosis reduces metabolic enzyme activity and portal blood flow, impairing drug
clearance and prolonging elimination half-life, which necessitates dose reduction or extended dosing
intervals to prevent drug accumulation and toxicity. [CORRECT]
Q2: A 55-year-old patient with nephrotic syndrome is prescribed a highly protein-bound drug (95%
bound to albumin). What is the primary clinical concern regarding drug distribution in this patient?
A. Increased free drug concentration and enhanced pharmacologic effect
B. Decreased total drug concentration requiring higher doses
C. Increased volume of distribution and prolonged half-life
D. Decreased hepatic metabolism due to protein displacement
Correct Answer: A
Rationale: Nephrotic syndrome causes hypoalbuminemia, reducing available binding sites and
increasing the free (unbound) fraction of highly protein-bound drugs, which increases pharmacologic
effect and toxicity risk even when total drug levels appear therapeutic. [CORRECT]
, Q3: A primary care NP prescribes a sustained-release formulation of metformin for a patient with type 2
diabetes. Which pharmacokinetic parameter is primarily altered by this formulation compared to
immediate-release?
A. Absorption rate
B. Distribution volume
C. Hepatic metabolism
D. Renal excretion
Correct Answer: A
Rationale: Sustained-release formulations alter the absorption rate through controlled-release
technology, prolonging drug release from the formulation and producing a flatter plasma concentration-
time curve with reduced peak-trough fluctuations. [CORRECT]
Q4: A medication has a half-life of 8 hours and is dosed every 8 hours. Approximately how many doses
are required to reach 97% of steady-state concentration?
A. 2 doses
B. 3 doses
C. 4 doses
D. 5 doses
Correct Answer: D
Rationale: Steady-state is reached after approximately 4–5 half-lives; after 5 half-lives (40 hours, or 5
doses at q8h), the plasma concentration reaches approximately 97% of steady-state, which is the clinical
threshold for therapeutic assessment. [CORRECT]
Section 2: Pharmacodynamics (Questions 5–8)
Q5: A patient taking a non-selective beta-blocker for hypertension develops wheezing and
bronchospasm. The NP recognizes this as an adverse effect mediated by which pharmacodynamic
mechanism?
A. Agonism at beta-2 adrenergic receptors
B. Antagonism at beta-2 adrenergic receptors
C. Antagonism at muscarinic receptors
D. Agonism at alpha-1 adrenergic receptors
Correct Answer: B
Rationale: Non-selective beta-blockers antagonize beta-2 receptors in bronchial smooth muscle,
preventing endogenous catecholamine-mediated bronchodilation and causing bronchoconstriction,
which is particularly dangerous in patients with reactive airway disease. [CORRECT]
Care Week 1 Quiz 20-Question Practice Quiz
ACTUAL EXAM 2026/2027 | Chamberlain
NR 565 Week 1 | Verified Q&A | Pass
Guaranteed - A+ Graded
Section 1: Pharmacokinetics (Questions 1–4)
Q1: A 68-year-old patient with chronic heart failure and NASH-related cirrhosis is prescribed a new
medication that undergoes extensive first-pass metabolism in the liver. Which pharmacokinetic
alteration is most expected in this patient?
A. Decreased drug bioavailability
B. Increased drug half-life
C. Decreased volume of distribution
D. Increased protein binding
Correct Answer: B
Rationale: Hepatic cirrhosis reduces metabolic enzyme activity and portal blood flow, impairing drug
clearance and prolonging elimination half-life, which necessitates dose reduction or extended dosing
intervals to prevent drug accumulation and toxicity. [CORRECT]
Q2: A 55-year-old patient with nephrotic syndrome is prescribed a highly protein-bound drug (95%
bound to albumin). What is the primary clinical concern regarding drug distribution in this patient?
A. Increased free drug concentration and enhanced pharmacologic effect
B. Decreased total drug concentration requiring higher doses
C. Increased volume of distribution and prolonged half-life
D. Decreased hepatic metabolism due to protein displacement
Correct Answer: A
Rationale: Nephrotic syndrome causes hypoalbuminemia, reducing available binding sites and
increasing the free (unbound) fraction of highly protein-bound drugs, which increases pharmacologic
effect and toxicity risk even when total drug levels appear therapeutic. [CORRECT]
, Q3: A primary care NP prescribes a sustained-release formulation of metformin for a patient with type 2
diabetes. Which pharmacokinetic parameter is primarily altered by this formulation compared to
immediate-release?
A. Absorption rate
B. Distribution volume
C. Hepatic metabolism
D. Renal excretion
Correct Answer: A
Rationale: Sustained-release formulations alter the absorption rate through controlled-release
technology, prolonging drug release from the formulation and producing a flatter plasma concentration-
time curve with reduced peak-trough fluctuations. [CORRECT]
Q4: A medication has a half-life of 8 hours and is dosed every 8 hours. Approximately how many doses
are required to reach 97% of steady-state concentration?
A. 2 doses
B. 3 doses
C. 4 doses
D. 5 doses
Correct Answer: D
Rationale: Steady-state is reached after approximately 4–5 half-lives; after 5 half-lives (40 hours, or 5
doses at q8h), the plasma concentration reaches approximately 97% of steady-state, which is the clinical
threshold for therapeutic assessment. [CORRECT]
Section 2: Pharmacodynamics (Questions 5–8)
Q5: A patient taking a non-selective beta-blocker for hypertension develops wheezing and
bronchospasm. The NP recognizes this as an adverse effect mediated by which pharmacodynamic
mechanism?
A. Agonism at beta-2 adrenergic receptors
B. Antagonism at beta-2 adrenergic receptors
C. Antagonism at muscarinic receptors
D. Agonism at alpha-1 adrenergic receptors
Correct Answer: B
Rationale: Non-selective beta-blockers antagonize beta-2 receptors in bronchial smooth muscle,
preventing endogenous catecholamine-mediated bronchodilation and causing bronchoconstriction,
which is particularly dangerous in patients with reactive airway disease. [CORRECT]
